AI brief of an SEC Form 8-K · Organon & (OGN)

Organon 2024 revenue rose 2% to $6.4 billion, but GAAP EPS fell 17% to $3.33

Mixed Impact 3 of 5 earnings Written later

Organon reported fourth-quarter and full-year 2024 results and gave 2025 guidance. Full-year revenue rose 2% to $6.4 billion, but GAAP diluted EPS fell 17% to $3.33, and fourth-quarter GAAP net income dropped to $109 million from $546 million, a period that included a $476 million Swiss tax benefit. The 2025 revenue range of $6.125 billion to $6.325 billion sits below 2024 revenue, which shareholders should weigh against the company's adjusted margin outlook of 31.0% to 32.0%.

Key points

  • Q4 2024 revenue was $1.592 billion, flat with Q4 2023; diluted EPS was $0.42 versus $2.13, while non-GAAP adjusted diluted EPS was $0.90 versus $0.88
  • Full-year 2024 adjusted diluted EPS was $4.11 versus $4.14 in 2023; adjusted EBITDA margin was 30.6% versus 31.0%
  • 2025 guidance: revenue of $6.125 billion to $6.325 billion, including an approximate $200 million foreign exchange headwind; adjusted EBITDA margin of 31.0% to 32.0%
  • Board declared a quarterly dividend of $0.28 per share, payable March 13, 2025, to holders of record on February 24, 2025

The filing

CompanyOrganon & (OGN)
Form8-K, current report
Filed with the SECFeb 13, 2025, 8:01 AM ET
Accession number0001104659-25-012546

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 13, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.